New immuno-therapies are transforming the treatment landscape for a number of diseases, from cancer to autoimmune conditions. They could also aid the treatment of infectious diseases, such as COVID-19. But these therapies are only as good as the access to them. Dr. Jennifer Buell, the President and COO of the immuno-oncology discovery and development firm, Agenus, explores frontiers in immuno-therapies and explains how to get the best new treatments and combination therapies to the most patients. This sponsored discussion, hosted by Jeremy Abbate, the Publisher of Scientific American, is part of the series, 18 Minutes With.
18 Minutes With is a discussion series from Scientific American Custom Media, produced with support from and in collaboration with Agenus. Please visit Agenus to learn more about the company’s work in immuno-oncology.
